Optimizing drug delivery, bioavailability, and bioequivalence.

Tariq Mahmood*

Department of Clinical Pharmacology, Lahore Institute of Pharmacy, Pakistan

Introduction

The realm of drug delivery continually seeks breakthroughs to enhance therapeutic outcomes, especially when dealing with complex molecules. A prominent area of investigation is the oral delivery of peptide and protein drugs, which inherently face considerable challenges such as rapid enzymatic degradation within the gastrointestinal tract and inherently poor membrane permeability. To circumvent these obstacles, researchers are exploring and developing innovative formulation strategies. These include sophisticated nanocarriers, potent permeation enhancers, and clever prodrug designs, all aimed at significantly improving oral bioavailability and, consequently, the overall therapeutic efficacy of these vital drugs [1]

. Beyond peptides and proteins, drugs with low water solubility also present a substantial barrier to effective oral administration. Here, lipid-based drug delivery systems (LBDDS) have emerged as a critical advancement, offering a promising solution to enhance the oral bioavailability of these challenging compounds. This approach involves various LBDDS formulations, each designed with specific mechanisms of action that effectively overcome the physiological absorption barriers, leading to marked improvements in drug dissolution rates and subsequent absorption into the body [2]

. Building on advanced delivery concepts, the application of various nanoparticle formulations has proven particularly impactful in enhancing the oral bioavailability of anti-cancer drugs. Nanoparticles provide a versatile platform to address multiple challenges simultaneously, including the notorious issues of poor drug solubility, susceptibility to degradation, and efflux mechanisms that often limit therapeutic efficacy. Their use has led to significantly improved therapeutic outcomes and a reduction in unwanted systemic toxicity, offering a more targeted and efficient approach to cancer treatment [3]

. In the broader context of drug development, demonstrating bioequivalence is a crucial regulatory step, ensuring that generic products are therapeutically interchangeable with their reference counterparts. This process becomes notably intricate for orally inhaled drug products (OIDPs). Regulatory frameworks meticulously outline the scientific principles and the required methodologies, involving both rigorous in vitro and in vivo studies, to conclusively establish that generic OIDPs achieve the same therapeutic effect as existing reference products, thereby ensuring patient safety and efficacy [4]

. Further refining oral delivery for challenging therapeutics, recent progress in specialized oral delivery systems specifically targets improving the pharmacokinetic profiles of peptides and proteins. These systems move beyond basic delivery, focusing on how the drug is absorbed, distributed, metabolized, and excreted. Novel formulation strategies, such as diverse nanocarriers and strategic chemical modifications, are meticulously engineered to overcome the formidable gastrointestinal barriers and mitigate enzymatic degradation, ultimately leading to enhanced systemic exposure and improved patient responses [5]

. Beyond formulation, understanding and predicting drug behavior within the body is pivotal. Physiologically Based Pharmacokinetic (PBPK) modeling represents a sophisticated tool in this regard, offering the ability to forecast potential drug-drug interactions with high accuracy and effectively inform the design of clinical trials. These PBPK models integrate a comprehensive set of drug-specific and physiological parameters, allowing for precise predictions of in vivo drug behavior, which in turn leads to more efficient drug development processes and the potential for highly personalized dosing regimens tailored to individual patient needs [6]

. The complexities of bioequivalence extend beyond oral and inhaled routes to topical dermatological drug products. Establishing interchangeability for these products involves navigating a challenging regulatory and scientific landscape. Traditional in vivo studies often present limitations, which has spurred the emergence of alternative and complementary approaches, such as in vitro release and permeation tests (IVRT/IVPT). These innovative testing methods aim to provide robust evidence for product interchangeability, thereby streamlining development and ensuring consistent patient outcomes [7]

. For drugs characterized by poor solubility, developing oral sustained-release formulations presents its own unique set of challenges and opportunities. The goal is to maintain therapeutic drug levels over extended periods, which requires overcoming inherent

***Correspondence to:** Tariq Mahmood, Department of Clinical Pharmacology, Lahore Institute of Pharmacy, Pakistan. E-mail: tariq.mahmood@pharmaknowledge.pk

Received: 05-May-2025, Manuscript No. AAJPTR-25-205; **Editor assigned:** 07-May-2025, Pre QC No. AAJPTR-25-205 *(PQ)*; **Reviewed:** 27-May-2025, QC No. AAJPTR-25-205; **Revised:** 05-Jun-2025, Manuscript No. AAJPTR-25-205 *(R)*; **Published:** 16-Jun-2025, DOI: 10.35841/aajptr-9.3.205

Citation: Mahmood T. Optimizing drug delivery, bioavailability, and bioequivalence. J Pharmacol Ther Res. 2025;09(03):205.

solubility and dissolution rate limitations. This area of research explores various innovative formulation strategies, including advanced matrix systems and sophisticated osmotic pumps, all designed to ensure prolonged drug action and improved patient compliance [8]

. A cornerstone of assessing drug product quality and performance, particularly for complex oral drug products, is dissolution testing. This method plays a critical role as a reliable surrogate for evaluating in vivo performance and establishing bioequivalence. The emphasis is on advanced dissolution methods and their strong correlation with pharmacokinetic outcomes, a relationship that is indispensable for successful generic drug development and maintaining stringent quality control standards across the pharmaceutical industry [9]

. Further enhancing our understanding of drug dynamics, population pharmacokinetic (PopPK) modeling and simulation are applied comprehensively throughout the entire drug development process. This powerful approach allows researchers to delve into drug variability among diverse patient populations, optimize complex dosing regimens for maximum efficacy and safety, and provide crucial data to support informed regulatory decisions. Ultimately, PopPK modeling contributes significantly to more efficient drug development pathways and the realization of truly personalized drug therapy [10]

. These diverse research fronts collectively highlight the ongoing innovation aimed at improving drug delivery, absorption, and regulatory assessment, paving the way for more effective and safer therapeutic interventions.

Conclusion

Drug development faces significant hurdles, especially in enhancing oral bioavailability for complex molecules like peptides and proteins, which often encounter enzymatic degradation and poor membrane permeability. Advanced strategies, including various nanocarriers, permeation enhancers, and prodrugs, are explored to overcome these issues. Similarly, lipid-based drug delivery systems and nanoparticle formulations improve the oral bioavailability of poorly water-soluble drugs and anti-cancer agents, respectively, by addressing solubility, degradation, and efflux mechanisms. Beyond formulation, ensuring therapeutic equivalence is crucial. Regulatory frameworks for bioequivalence are detailed for orally inhaled drug products and topical dermatological drug products, highlighting both in vivo studies and alternative in vitro methods like IVRT/IVPT. Sustained-release formulations for poorly soluble drugs also aim to maintain therapeutic levels over time, employing matrix systems and osmotic pumps. Predictive tools like Physiologically Based Pharmacokinetic (PBPK) and Population Pharmacokinetic (PopPK) modeling are vital. PBPK models help forecast drug-drug interactions and guide clinical trials, while PopPK models analyze drug variability and optimize dosing regimens. Dissolution testing is also essential as a surrogate for in vivo performance and bioequivalence, particularly for complex oral products, influencing generic drug development and quality control. Together, these areas represent a multifaceted approach to improving drug efficacy, safety, and development efficiency.

References

1. Shufang C, Kai W, Jialin W. Overcoming challenges in oral peptide and protein drug delivery: *Recent advances in formulation strategies. J Control Release.* 2024;368:18-35.
2. Yixuan Z, Wenwen L, Tao Y. Recent advances in lipid-based drug delivery systems for enhanced oral bioavailability of poorly water-soluble drugs. *J Control Release.* 2022;346:367-380.
3. Sarita G, Rishi K, Surendra KG. Nanoparticle-based formulations for improved oral bioavailability of anti-cancer drugs: *Recent advances and future perspectives. Biomed Pharmacother.* 2021;139:111956.
4. Anjana R, Lawrence XY, Robert L. Bioequivalence considerations for orally inhaled drug products: *A regulatory perspective. AAPS J.* 2019;21:92.
5. Tao R, Tao Z, *Peng Y. Recent advances in oral drug delivery systems for improving the pharmacokinetics of therapeutic peptides and proteins. J Control Release.* 2023;362:133-149.
6. Xinyi Z, Dandan S, Li Z. Application of physiologically based pharmacokinetic modeling in predicting drug-drug interactions and guiding clinical trials. *Acta Pharm Sin B.* 2021;11:10-23.
7. Mustafa G, Maitha A, Ahlam A. Bioequivalence of topical dermatological drug products: *Current regulatory landscape and scientific challenges. Int J Pharm.* 2020;588:119777.
8. Mohammad A, Rania MO, Mahmoud AA. Oral sustained-release formulations of poorly soluble drugs: *Challenges and opportunities. J Pharm Sci.* 2023;112:1832-1845.
9. Jian Z, Hao Z, *Ying M. The role of dissolution testing in predicting in vivo performance and bioequivalence for complex oral drug products. J Pharm Sci.* 2022;111:3045-3058.
10. Huiling L, Ying F, Zhenbo S. Population pharmacokinetic modeling and simulation in drug development: *A comprehensive review. AAPS J.* 2020;22:116.

Citation: *Mahmood T. Optimizing drug delivery, bioavailability, and bioequivalence. J Pharmacol Ther Res. 2025;09(03):205.*